Humanigen, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies

Other Names/Subsidiaries

  • KaloBios Pharmaceuticals, Inc.
  • Humanigen Australia Pty Ltd
See more in Biomedtracker

Latest on Humanigen, Inc.

Scrip

News In Brief: Sotyktu Phase III Win, Novo’s Alhemo Approval, Axsome Agitation Data, Pfizer Gives Back Sangamo Gene Therapy

 
• By Mandy Jackson, Jessica Merrill, and Mary Jo Laffler

Bristol’s Sotyktu Passes Phase III Psoriatic Arthritis Test Bristol Myers Squibb reported positive topline results from two Phase III clinical trials of its TYK2 inhibitor Sotyktu (deucravacitinib) in

Scrip

Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success

 
• By Mandy Jackson

UroGen Pharma, Ltd. anticipated filing for US Food and Drug Administration approval in 2024 for UGN-102 in the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMI

Scrip

InflaRx Looks Ahead To Late 2023 Commercial Sales For COVID-19 Antibody

 
• By Alaric DeArment

InflaRx N.V. anticipates seeing commercial sales toward the second half of the year of Gohibic (vilobelimab) following the drug’s emergency use authorization (EUA) from the US Food and Drug Administr

Scrip

Humanigen Isn’t Throwing In The Towel On Lenzilumab For COVID-19 Just Yet

 
• By Alaric DeArment

The mostly negative result of a Phase III trial of Humanigen, Inc. ’s anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) drug lenzilumab in cytokine storm associated with COVID-19 came as